



# **BE PROACTIVE.**

## **Learn About Proleukin®.**

**Access these resources for Proleukin  
information, stories of real patients,  
peer support, and patient assistance**



For injection  
**PROLEUKIN®**  
(aldesleukin) Recombinant IL-2

Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma or metastatic melanoma.

Please see enclosed full Prescribing Information including **Boxed Warning**.  
Please see back page for Important Safety Information.

## ACCESS WITH A CLICK



Visit **www.Proleukin.com** to see how Proleukin has helped others and why it may be the right choice for you right now. Learn how Proleukin works, clinical study results, side effects, what makes Proleukin different, and more, including:

**www.Proleukin.com**

### The Proleukin Experience

Read stories and watch videos with first-hand accounts of patients who took Proleukin—candid stories about their condition, treatment, side effects, and life after Proleukin. Also watch an informative video in which doctors share their Proleukin knowledge and experience.

### The Proleukin Mentor Program

Learn program details and how you can sign up online to speak one-on-one with a mentor—a Proleukin patient who once faced what you're facing now and can share his or her personal experience.




### The Proleukin Treatment Center Finder



Proleukin should only be given at an experienced treatment center. Use this handy online tool to find the address and phone number of a treatment center that can answer your questions and introduce you to the treatment team.

## ACCESS WITH A CALL



### The Proleukin Patient Assistance Program

If you are considering or receiving Proleukin treatment, specialists are available to:

- Answer questions about health insurance plans and coverage
- Help you obtain prior authorization
- Aid you with claims denials
- Locate other sources of support for which you may qualify

**Proleukin Patient  
Assistance Program**  
**Call 1-877-776-5385**

Monday-Friday  
7:30 AM to 4:30 PM Pacific Time

### Patient Services, Inc.

This independent nonprofit organization provides financial assistance for qualifying patients and/or a loved one to help offset costs for travel, lodging, meals, and other related expenses associated with inpatient treatment for metastatic melanoma and metastatic kidney cancer.

**Patient Services, Inc.**  
**Call 1-800-366-7741**  
for more information

Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma or metastatic melanoma.

Please see enclosed full Prescribing Information including

#### Boxed Warning.

Please see next page for Important Safety Information.



Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma or metastatic melanoma.

## IMPORTANT Safety Information

Therapy with Proleukin® (aldesleukin) should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should be used in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.

Proleukin should be administered in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.

Proleukin administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias

(supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.

Proleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of Proleukin therapy. Patients with indwelling central lines are particularly at risk for infection with gram positive microorganisms.

Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.

Proleukin administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.

Please see enclosed full Prescribing Information including **Boxed Warning**.



PROMETHEUS®  
Therapeutics & Diagnostics

PROMETHEUS and the Link Design are registered trademarks of Prometheus Laboratories Inc. Proleukin and the swirl design are registered trademarks of Novartis Vaccines & Diagnostics, Inc. ©2012 Prometheus Laboratories Inc. All rights reserved. PRO12001 1/12